




Name	Satoshi Takahashi	
Current Position	Project professor	
Country	Japan	
Major Field	Cord Blood Transplant Cellular therapy for viral infection Precision medicine in myeloid malignancies	

Educational Background

1980-1986: Iwate Medical University, School of Medicine.

Professional Experience

- 1990-1998: Clinical and Research Associate, Department of Internal Medicine, IMSUT
- 1993-1998: Chief, BMT Program, IMSUT
- 1998-2001: Research fellow, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA
- 2002-2005: Assistant Professor/ Lecturer, Department of Hematology and Oncology, Chief, BMT Program, IMSUT
- 2002-present: Director, Adult Hematopoietic Stem Cell Transplant Program, IMSUT
- 2005-2021: Associate Professor, Division of Molecular therapy, Advanced Clinical Research Center, IMSUT
- 2021-present: Project Professor, Division of Clinical Precision Medicine Platform, Department of Hematology/Oncology, Division of Stem Cell Transplantation, Center for Gene & Cell Therapy, IMSUT

Other Experience and Professional Memberships

- The Japan Society for Transplantation and Cellular Therapy (JSTCT)
 - 2006- Board member,
 - 2014- Chair of International Committee,
 - 2018- Vice-Chairperson of the Board
 - 2022 President of the annual society meeting (JSTCT2022)
- American Society of Hematology (ASH)
 - 1996- Member
- Japanese Society of Immunotherapy for Hematological Disorders (JSIHDS)
 - 2006- Council member,
 - 2016- Board member
 - 2018 President of the annual society meeting
- International Society for Cell & Gene Therapy (ISCT)
 - 2015-2017 Regional Vice-President in Elect, Asia Regional Executive Committee
 - 2017-2019 Regional Vice-President, Asia Regional Executive Committee



Main Scientific Publications

1. Sakurai M, Ishitsuka K, Ito R, Wilkinson AC, Kimura T, Mizutani E, Nishikii H, Sudo K, Becker HJ, Takemoto H, Sano T, Kataoka K, **Takahashi S**, Nakamura Y, Kent DG, Iwama A, Chiba S, Okamoto S, Nakauchi H, Yamazaki S. Chemically defined cytokine-free expansion of human haematopoietic stem cells. *Nature*. 2023 Mar;615(7950):127-133. doi: 10.1038/s41586-023-05739-9. Epub 2023 Feb 22. PMID: 36813966.
2. Matsuda K, Konuma T, Fuse K, Masuko M, Kawamura K, Hirayama M, Uchida N, Ikegame K, Wake A, Eto T, Doki N, Miyakoshi S, Tanaka M, **Takahashi S**, Onizuka M, Kato K, Kimura T, Ichinohe T, Takayama N, Kobayashi H, Nakamae H, Atsuta Y, Kanda J, Yanada M. Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study. *Br J Haematol*. 2022 Oct 25. doi: 10.1111/bjh.18530. Epub ahead of print. PMID: 36281887.
3. Wada F, Watanabe M, Konuma T, Okabe M, Kobayashi S, Uchida N, Ikegame K, Tanaka M, Sugio Y, Mukae J, Onizuka M, Kawakita T, Kuriyama T, **Takahashi S**, Fukuda T, Nakano N, Sawa M, Kimura T, Ichinohe T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation. HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation. *Am J Hematol*. 2022 Jan 3. 97(3):311-321. doi: 10.1002/ajh.26446.
4. Nakamura S, Yokoyama K, Shimizu E, Yusa N, Kondoh K, Ogawa M, Takei T, Kobayashi A, Ito M, Isobe M, Konuma T, Kato S, Kasajima R, Wada Y, Nagamura-Inoue T, Yamaguchi R, **Takahashi S**, Imoto S, Miyano S, Tojo A. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. *Blood*. 133(25): 2682-2695. 2019 Apr 1. pii: blood-2018-10-880690. doi: 10.1182/blood-2018-10-880690.
5. **Takahashi S**, Ooi J, Tomonari A, Konuma T, Tsukada N, Maki Oiwa-Monna, Fukuno K, Uchiyama M, Takasugi K, K, Iseki T, Tojo A, Yamaguchi T, Asano S. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem cell transplantation from related donors in adult patients with hematological malignancies after myeloablative conditioning regimen. *Blood*, 109: 1322-1330, 2007.